Intrinsic Value of S&P & Nasdaq Contact Us

Revvity, Inc. RVTY NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
56/100
2/7 Pass
SharesGrow Intrinsic Value
$66.26
-29.1%
Analyst Price Target
$115.14
+23.1%

Revvity, Inc. (RVTY) generated $581.78M in operating cash flow for fiscal year 2025. After capital expenditures of $73.52M, free cash flow was $508.26M.

Free cash flow margin was 17.8% of revenue. Cash conversion ratio was 2.41x, indicating earnings are backed by cash.

The company returned $32.8M in dividends and $820.82M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
  • INCOME (45/100) — Cash conversion ratio was 2.41x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
56/100
SG Score
View full scorecard →
VALUE
27/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
58/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
83/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
65/100
Proven by this page
GROWTH
15/100
→ Income
~
INCOME
45/100
→ Income
Revvity, Inc. Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $584.33M$581.78M$628.3M$91.27M$679.81M
Capital Expenditure $-73.52M$-73.52M$-86.65M$-81.37M$-85.63M
Free Cash Flow $510.81M$508.26M$541.65M$9.9M$594.18M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message